| Autor: |
Min Yuen Teo, Brendan J. Guercio, Arshi Arora, Xueli Hao, Ashley M. Regazzi, Timothy Donahue, Harry W. Herr, Alvin C. Goh, Eugene K. Cha, Eugene Pietzak, Sherri M. Donat, Guido Dalbagni, Bernard H. Bochner, Semra Olgac, Judy Sarungbam, S. Joseph Sirintrapun, Ying-Bei Chen, Anuradha Gopalan, Samson W. Fine, Satish K. Tickoo, Victor E. Reuter, Britta Weigelt, Anne M. Schultheis, Samuel A. Funt, Dean F. Bajorin, David B. Solit, Gopa Iyer, Irina Ostrovnaya, Jonathan E. Rosenberg, Hikmat Al-Ahmadie |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Clin Genitourin Cancer |
| ISSN: |
1558-7673 |
| DOI: |
10.1016/j.clgc.2022.05.005 |
| Popis: |
INTRODUCTION: Small cell carcinoma of the bladder (SCCB) is a rare variant of bladder cancer with poor outcomes. We evaluated long-term outcomes of nonmetastatic (M0) and metastatic (M1) SCCB and correlated pathologic response with genomic alterations of patients treated with neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS: Clinical history and pathology samples from SCCB patients diagnosed at our institution were reviewed. RESULTS: One hundred and ninety-nine SCCB patients were identified. (M0: 147 [74%]; M1: 52 [26%]). Among M0 patients, 108 underwent radical cystectomy (RC) (NAC: 71; RC only: 23; adjuvant chemotherapy: 14); 14 received chemoradiotherapy; the rest received chemotherapy alone or no cancer-directed therapy. RC-only patients had a median follow-up of 9.1 years, and median disease-free survival (DFS) and overall survival (OS) were 1.1 and 1.2 years, respectively. NAC patients had pathologic response ( |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect